These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27539851)

  • 41. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.
    Han S; Ren Y; He W; Liu H; Zhi Z; Zhu X; Yang T; Rong Y; Ma B; Purwin TJ; Ouyang Z; Li C; Wang X; Wang X; Yang H; Zheng Y; Aplin AE; Liu J; Shao Y
    Nat Commun; 2018 Jan; 9(1):28. PubMed ID: 29295999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization.
    Lim JH; Luo C; Vazquez F; Puigserver P
    Cancer Res; 2014 Jul; 74(13):3535-45. PubMed ID: 24812272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic and mind shifts: from glucose to glutamine and acetate addictions in cancer.
    Corbet C; Feron O
    Curr Opin Clin Nutr Metab Care; 2015 Jul; 18(4):346-53. PubMed ID: 26001655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.
    Hardeman KN; Peng C; Paudel BB; Meyer CT; Luong T; Tyson DR; Young JD; Quaranta V; Fessel JP
    Sci Rep; 2017 Feb; 7():42604. PubMed ID: 28205616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nutrient utilization by cells isolated from rat jejunum, cecum and colon.
    Fleming SE; Fitch MD; DeVries S; Liu ML; Kight C
    J Nutr; 1991 Jun; 121(6):869-78. PubMed ID: 1903440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The ASCT/SCS cycle fuels mitochondrial ATP and acetate production in Trypanosoma brucei.
    Mochizuki K; Inaoka DK; Mazet M; Shiba T; Fukuda K; Kurasawa H; Millerioux Y; Boshart M; Balogun EO; Harada S; Hirayama K; Bringaud F; Kita K
    Biochim Biophys Acta Bioenerg; 2020 Nov; 1861(11):148283. PubMed ID: 32763239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BNIP3 contributes to the glutamine-driven aggressive behavior of melanoma cells.
    Vara-Perez M; Maes H; Van Dingenen S; Agostinis P
    Biol Chem; 2019 Jan; 400(2):187-193. PubMed ID: 29924728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Properties and substrate specificity of some reactions catalysed by a short-chain fatty acyl-coenzyme A synthetase from seeds of Pinus radiata.
    Young OA; Anderson JW
    Biochem J; 1974 Mar; 137(3):423-33. PubMed ID: 4370976
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma.
    Smith LK; Rao AD; McArthur GA
    Pharmacol Res; 2016 May; 107():42-47. PubMed ID: 26924126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acetate and propionate potentiate the antiproliferative effect of butyrate on RBL-2H3 growth.
    Vecchia MG; Carnelós Filho M; Fellipe CR; Curi R; Newsholme EA
    Gen Pharmacol; 1997 Nov; 29(5):725-8. PubMed ID: 9347317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
    Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
    Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acetate dependence of tumors.
    Comerford SA; Huang Z; Du X; Wang Y; Cai L; Witkiewicz AK; Walters H; Tantawy MN; Fu A; Manning HC; Horton JD; Hammer RE; McKnight SL; Tu BP
    Cell; 2014 Dec; 159(7):1591-602. PubMed ID: 25525877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.
    Corazao-Rozas P; Guerreschi P; André F; Gabert PE; Lancel S; Dekiouk S; Fontaine D; Tardivel M; Savina A; Quesnel B; Mortier L; Marchetti P; Kluza J
    Oncotarget; 2016 Jun; 7(26):39473-39485. PubMed ID: 27250023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
    Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
    Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets.
    Konstantakou EG; Velentzas AD; Anagnostopoulos AK; Litou ZI; Konstandi OA; Giannopoulou AF; Anastasiadou E; Voutsinas GE; Tsangaris GT; Stravopodis DJ
    PLoS One; 2017; 12(2):e0171512. PubMed ID: 28158294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization.
    Björnson E; Mukhopadhyay B; Asplund A; Pristovsek N; Cinar R; Romeo S; Uhlen M; Kunos G; Nielsen J; Mardinoglu A
    Cell Rep; 2015 Dec; 13(9):2014-26. PubMed ID: 26655911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
    Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG
    Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
    Furlan T; Khalid S; Nguyen AV; Günther J; Troppmair J
    Mol Oncol; 2018 Jun; 12(6):869-882. PubMed ID: 29624862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
    Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.